Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) CFO Susan Hohenleitner sold 2,033 shares of the firm's stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $5.85, for a total value of $11,893.05. Following the sale, the chief financial officer owned 230,533 shares in the company, valued at approximately $1,348,618.05. The trade was a 0.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Ardelyx Stock Up 0.3%
NASDAQ ARDX opened at $5.75 on Tuesday. The company has a quick ratio of 4.11, a current ratio of 4.31 and a debt-to-equity ratio of 1.21. Ardelyx, Inc. has a fifty-two week low of $3.21 and a fifty-two week high of $8.40. The business has a 50 day moving average price of $6.76 and a two-hundred day moving average price of $6.13. The stock has a market cap of $1.40 billion, a PE ratio of -23.00 and a beta of 0.57.
Ardelyx (NASDAQ:ARDX - Get Free Report) last posted its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.03). The firm had revenue of $125.22 million for the quarter, compared to analysts' expectations of $118.04 million. Ardelyx had a negative net margin of 15.12% and a negative return on equity of 40.63%. The company's revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.02 EPS. As a group, sell-side analysts predict that Ardelyx, Inc. will post -0.18 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on ARDX. BTIG Research reaffirmed a "buy" rating and set a $17.00 target price on shares of Ardelyx in a research report on Friday. TD Cowen restated a "buy" rating on shares of Ardelyx in a research note on Thursday, January 29th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $15.00 target price on shares of Ardelyx in a research report on Tuesday, January 27th. HC Wainwright increased their target price on Ardelyx from $10.00 to $18.00 and gave the company a "buy" rating in a research note on Friday. Finally, Citigroup lifted their price target on shares of Ardelyx from $11.00 to $14.00 and gave the stock a "buy" rating in a research note on Friday, January 9th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Ardelyx presently has a consensus rating of "Buy" and a consensus target price of $15.09.
View Our Latest Stock Report on ARDX
Institutional Investors Weigh In On Ardelyx
Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Ardelyx by 3.3% during the fourth quarter. Vanguard Group Inc. now owns 18,979,483 shares of the biopharmaceutical company's stock worth $110,650,000 after purchasing an additional 610,162 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of Ardelyx by 5.0% in the 4th quarter. Janus Henderson Group PLC now owns 14,514,692 shares of the biopharmaceutical company's stock worth $84,583,000 after buying an additional 690,599 shares during the last quarter. State Street Corp boosted its holdings in shares of Ardelyx by 22.6% in the 4th quarter. State Street Corp now owns 11,912,339 shares of the biopharmaceutical company's stock valued at $69,449,000 after buying an additional 2,193,649 shares during the period. Marshall Wace LLP grew its position in shares of Ardelyx by 34.2% during the 2nd quarter. Marshall Wace LLP now owns 11,250,652 shares of the biopharmaceutical company's stock valued at $44,103,000 after buying an additional 2,866,843 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Ardelyx by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 5,827,618 shares of the biopharmaceutical company's stock valued at $33,981,000 after buying an additional 70,832 shares during the last quarter. 58.92% of the stock is owned by institutional investors and hedge funds.
More Ardelyx News
Here are the key news stories impacting Ardelyx this week:
- Positive Sentiment: Director David M. Mott purchased 333,333 shares (~$1.95M) at about $5.84, increasing his stake by ~11.2% — a strong insider vote of confidence that can support the stock. SEC Filing: Director Purchase
- Positive Sentiment: Wedbush reaffirmed an "outperform" rating and set a $19 price target (large upside vs. current levels), which can attract buyers and boost sentiment. Wedbush Note via Benzinga
- Positive Sentiment: Other firms reiterated bullish views (BTIG buy rating; HC Wainwright optimistic on FY2026 earnings), reinforcing analyst support that can sustain buying interest. BTIG Reiteration HC Wainwright Note
- Neutral Sentiment: Quarterly revenue beat estimates ($125.2M vs. $118.0M) and year-over-year revenue growth of ~7.8% — a constructive fundamental datapoint, though offset by an EPS miss. (Earnings release was on Feb 19.)
- Negative Sentiment: Earnings EPS missed expectations (reported a loss vs. small expected profit), which triggered a sell-off (shares were reported down ~10.4% after the earnings release). EPS misses typically pressure sentiment and can lead to continued volatility. Earnings Reaction
- Negative Sentiment: Multiple insiders — including the CEO, CFO and several executives — sold shares on Feb 20 (notably the CEO sold ~45,982 shares). Clustered insider selling can be read as profit-taking or reduced insider conviction and may weigh on sentiment. (These sales occurred near $5.85.) SEC Filing: CEO Sale
Ardelyx Company Profile
(
Get Free Report)
Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company's lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx's proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.
Beyond tenapanor, Ardelyx's development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
